Argenx

This study tested a drug called efgartigimod in 98 adults with moderate to severe bullous pemphigoid, a condition that causes painful blisters and itching. The goal was to see if the drug could help people achieve complete remission (no new blisters, healed skin, no itching) whil…

This study tested a drug called efgartigimod in 101 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal was to see if the drug is safe and helps maintain healthy platelet levels over a year. P…

This study tested the long-term safety of a drug called efgartigimod in 184 adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants received repeated injections over weeks, as needed, to see if the treatment was safe and helped with daily …

This study looks at the long-term safety of a drug called efgartigimod for adults with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. Participants had already completed a previous efgartigimod study. The drug works by lowering harmful antibodies…

This study looked at whether adults with CIDP, a nerve disorder, could switch from their regular IVIg infusions to a new injected medicine called efgartigimod PH20 SC. 23 participants stopped IVIg and started the new treatment, staying on it for 12 weeks. The main goal was to see…

This study tested a new drug called ARGX-117 in 54 adults with multifocal motor neuropathy (MMN), a rare nerve condition that causes muscle weakness. Participants were already stable on regular IVIg infusions. The goal was to see if ARGX-117 is safe and can delay the need for IVI…

This study tested two ways of giving the drug efgartigimod to people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. One group received the drug on a regular, continuous schedule, while the other got it in cycles. The goal was to see which appro…

This study tested a drug called efgartigimod in 73 Chinese adults with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if the drug could reduce protein in the urine and improve kidney function over 24 weeks. Participants received either the drug or a…

This early-stage study tested the safety of a new drug called ARGX-213 in 88 healthy adults. Researchers also measured how the drug moves through the body and affects immune markers. The study is complete and helps lay the groundwork for future research, but offers no direct trea…

This early-stage study tested the safety of a single dose of ARGX-109 in 40 healthy adults aged 18 to 65. Researchers also measured how the drug moves through the body and how it affects immune signals. No treatment was given for any disease; the goal was simply to gather initial…